KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Average (2016 - 2025)

TherapeuticsMD's Equity Average history spans 14 years, with the latest figure at $27.2 million for Q4 2025.

  • For Q4 2025, Equity Average changed 0.26% year-over-year to $27.2 million; the TTM value through Dec 2025 reached $27.2 million, changed 0.26%, while the annual FY2025 figure was $27.1 million, 4.26% down from the prior year.
  • Equity Average reached $27.2 million in Q4 2025 per TXMD's latest filing, down from $27.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $33.6 million in Q1 2023 to a low of -$117.1 million in Q1 2022.
  • Average Equity Average over 5 years is -$6.3 million, with a median of $27.1 million recorded in 2025.
  • Peak YoY movement for Equity Average: plummeted 270.68% in 2021, then skyrocketed 536.77% in 2023.
  • A 5-year view of Equity Average shows it stood at -$75.5 million in 2021, then skyrocketed by 91.3% to -$6.6 million in 2022, then surged by 536.77% to $28.7 million in 2023, then fell by 5.01% to $27.2 million in 2024, then fell by 0.26% to $27.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Equity Average are $27.2 million (Q4 2025), $27.4 million (Q3 2025), and $27.0 million (Q2 2025).